glp 1 disorders Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge eating disorder? And how can clinicians protect patients from risk? Harm Reduction for Eating Disorders

Although the relationship between GLP-1RAs and thyroid cancer risk remains uncertain, caution is advised when prescribing GLP-1RAs in individuals with a history of thyroid cancer or in those with higher risk [24]

A year later, those on the medication lost about 8 percent of their weight

[DOI] [PubMed] [Google Scholar] 519.Grasset E., Puel A., Charpentier J., Collet X., Christensen J.E., Terce F

Semaglutide (Wegovy) and tirzepatide (Zepbound) have demonstrated significant average weight loss14.9% and 20.9% of body weight at approximately one year, respectively

1 Due to its longer duration of action, it is typically administered subcutaneously once weekly

found that the use of exenatide once weekly has nonsignificant effects on LDL-C levels with a change of -0.05 mmol/L 0.05 mmol/L, suggesting that the effect of GLP-1 RAs on LDL-C levels requires further research [67]